The Claim
Semaglutide treatment in obese ZSF1 rats with HFpEF reduces the hepatic expression of fibrosis-promoting genes including Col4a1, Emilin1, Bgn, and Klf10, indicating a potential inhibition of liver fibrotic pathways.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese rats with heart failure and preserved ejection fraction, semaglutide reduces the activity of specific genes in the liver that are involved in scar tissue formation, suggesting it may lessen liver fibrosis.
See the scientific wording
In obese ZSF1 rats with HFpEF, semaglutide treatment downregulates hepatic expression of fibrosis-promoting genes including Col4a1, Emilin1, Bgn, and Klf10, suggesting a potential suppression of liver fibrotic pathways.
A signaling molecule binds to receptors on liver cells, turning down genes that make scar tissue and turning up genes that break down fats and use amino acids for energy. This reduces fat buildup and prevents the liver from stiffening and scarring.
What the research says
1 studyIn obese rats with heart failure, a drug called semaglutide lowered the activity of genes that cause scar tissue to form in the liver — meaning it may help prevent liver damage, even without making the rats lose weight.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.